Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458611 | 0.88 | OGA (0.42) | RAB9AKDM4ECNR2OGANAMPT | |
| SCHEMBL15051480 | 0.86 | OGA (0.44) | RAB9AOGANAMPTNPC1SMN1; SMN2 | |
| SCHEMBL458850 | 0.84 | MAPT (0.50) | RAB9AKDM4ENAMPTNPC1SMN1; SMN2 | |
| SCHEMBL459750 | 0.81 | OGA (0.41) | RAB9AKDM4EOGANAMPTHSD17B10 | |
| Morpholine SCHEMBL17233473 | 0.80 | CNR2 (0.42) | RAB9ACNR2OGANAMPTNPC1 | |
| SCHEMBL460222 | 0.78 | CNR2 (0.47) | CNR2PIK3CAOGA | |
| SCHEMBL458505 | 0.77 | CNR2 (0.49) | CNR2OGA | |
| SCHEMBL27900548 | 0.77 | CNR2 (0.39) | RAB9AKDM4ECNR2OGANPC1 | |
| SCHEMBL460287 | 0.77 | ALDH1A1 (0.53) | RAB9AKDM4ENPC1SMN1; SMN2TP53 | |
| SCHEMBL458766 | 0.77 | CNR2 (0.40) | GRM5RAB9ACNR2OGANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181183-B2 | Prostaglandin D synthase inhibitory piperidine compounds | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | claimed |
| EP-2615084-B1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9181183-B2 | Prostaglandin D synthase inhibitory piperidine compounds | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2615084-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | US | disclosed |
| WO-2012033069-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | 大鵬薬品工業株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | PTGIS, PTGS1, PTGDR | GRM5 1905/4885RAB9A 3049/4885KDM4E 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.